Novo Nordisk CSO warns NASH market will develop slowly, urges all to 'moderate expectations'

Mads Krogsgaard Thomsen, Novo Nordisk (NOV: N) employee for over a quarter of a century, says he has "been through all the miserable failures as well as the successes of the company, from products that are now off patent to those that don't yet have one."

Professor Thomsen, who calls himself "a bit of an old timer," joined the firm in 1991 as head of growth hormone research, and subsequently worked in diabetes as head of research before leading R&D for the whole company and becoming chief scientific officer at the turn of the millennium.

As 2017 draws to a close, The Pharma Letter caught up with him to discover highlights from the year that was, and a look ahead to the key events for Novo Nordisk next year.